Is Canopy Growth (TSX:WEED) a Bargain Stock?

After falling precipitously for months, Canopy Growth Corp (TSX:WEED)(NYSE:CGC) has been deemed a bargain by its former CEO. Is it?

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

High insider ownership is usually considered a good sign for a stock’s future prospects. When people who know everything about a company’s operations buy it, it indicates that the stock has a good future — or so the theory goes.

Enter Canopy Growth (TSX:WEED)(NYSE:CGC).

Recently, it was revealed that the company’s ex-CEO Bruce Linton had been buying up shares, calling its August beatdown a “sale,” and re-affirming his belief in the company’s long-term soundness. Prior to this, investors had sent WEED shares tanking after a surprise earnings release that showed an unprecedented $1.3 billion net loss.

Although he’s technically no longer a Canopy insider, Linton was on the inside as recently as last quarter. This means that his opinion on Canopy may be worth listening to. Before assessing whether Bruce Linton is correct about this “sale,” let’s look at some of the criteria investors use to decide whether a stock is a bargain.

What makes a stock a bargain?

For value investors, stocks are generally considered cheap when their share price is low compared to their discounted future cash flows. The word future is key here, because it means that there’s no accurate way to measure the most important metric. Past cash flows don’t necessarily indicate future cash flows, and earnings projections can falter just as much as stock price forecasts.

To compensate for the lack of data on discounted future cash flows, value investors use a number of metrics to value shares. The price-to-earnings (P/E) ratio measures a stock’s price against its trailing 12-month earnings. The price-to-sales (P/S) ratio measures price against sales, which don’t necessarily indicate profitability but may be the only metric available for young companies that are still losing money. Finally, the P/E-to-growth ratio measures a company’s price and earnings against its earnings-growth rate.

Is Bruce Linton right?

With a basic understanding of metrics that value investors use to decide whether a stock is “on sale,” we can now tackle the main question: Is Canopy “on sale?”

Unfortunately, it’s not going to be an easy one to answer.

For one thing, the company is not profitable, so the trailing P/E ratio isn’t applicable.

For another, while the P/S ratio (41) is still extremely high, the price-to-book ratio (2.1) is actually fairly reasonable, so what metrics we do have give us conflicting signals.

The company’s quarterly revenue growth rate (249% year over year) is unbelievably high, and if it can be maintained for several years, it may even justify a P/S ratio in the 40s.

Put simply, the valuation metrics available for Canopy are extremely hard to read, which may be why investors in this and other emerging growth stocks prefer to use technical analysis.

Foolish takeaway

Ultimately, I think Canopy is still overvalued, even after the August “sale” — the reason being that I don’t think its current revenue growth rate will be maintained into 2020. Whenever Canopy releases earnings this year, it compares post-legalization revenue to pre-legalization revenue, because all the comparable “last year” periods were from before legalization. Legalization was an enormous catalyst that gave weed companies a huge one-time revenue boost, and there are no other catalysts like this on the horizon. So, revenue growth rates will most likely slow in 2020, and these extraordinarily high P/S ratios will be harder to justify.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Button has no position in any of the stocks mentioned.

More on Cannabis Stocks

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »

A cannabis plant grows.
Cannabis Stocks

Can Aurora Cannabis Stock Recover in 2024?

Aurora Cannabis stock is down 99% from all-time highs but remains a high-risk bet, despite its cheap valuation.

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

The Best Cannabis Stock to Buy Right Now

This cannabis stock has jumped 30% in the last few months, with even more growth on the way – all…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Down 99% From All-Time Highs, Is Canopy Growth Stock a Good Buy Right Now?

Canopy Growth stock is a high-risk investment due to its negative profit margins and challenging liquidity position.

Read more »

Marijuana plant and cannabis oil bottles isolated
Stocks for Beginners

Aurora Cannabis’ Reverse Stock Split: Is the Stock a Buy Today?

Cannabis stock Aurora (TSX:ACB) is consolidating shares once again, but what does this mean for investors?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Where Will Cannabis Stocks Be in 10 Years?

Cannabis stocks could see a huge shift upwards should marijuana be rescheduled in the U.S., but you can still buy…

Read more »